TITLE:
Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!
AUTHORS:
Udaya M. Kabadi
KEYWORDS:
Review Paper
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.6 No.2,
April
20,
2016
ABSTRACT: It was interesting to read the recent
article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular
mortality [1]. Superficially, the report appears to be very promising. However,
the methodology, the results and the conclusions deserve and need further
scrutiny and validation for several reasons.